(pg13-a(f/k-f-sgsg-t2a-b (opt) (2g-1 tcr) retroviral vector-transduced lymphocyte
Gene therapyexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 2, 2009 (NCT00923390)
Timeline
2000s
- Jan 1, 2009
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigen
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- (pg13-a(f/k-f-sgsg-t2a-b (opt) (2g-1 tcr) retroviral vector-transduced lymphocyte
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00923390 | Phase 1 | Mar 2, 2009 | National Cancer Institute (NCI) |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 2009 |
1 organizations
Page 1 / 1